CLOVES Syndrome
5
3
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by High Intensity Focused Ultrasound
Research Leaders
8 sponsors active, led by Kaken Pharmaceutical
Related Conditions
Often studied with 20 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
20%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (5)
A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome
Lymphatic Anomalies Registry for the Assessment of Outcome Data
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Safety of the Sonablate HIFU System for the Ablation of Incompetent Veins of the Periphery
Research Network
Common Treatments
- High Intensity Focused Ultrasound1
- Kp0011
- National Registry1
- Rly26081
Active Sponsors
- Kaken Pharmaceutical1
- Vascular Breakthroughs, LLC1
- Boston Children's Hospital1
- Lymphatic Malformation Institute1
- Relay Therapeutics, Inc.1
Top Investigators
Boston Children's Hospital
Institut National de la Santé Et de la Recherche Médicale, France
The Vascular Care Group
Related Conditions
- Klippeltrenaunay Syndrome3
- Lymphatic Malformation2
- Blue Rubber Bleb Nevus Syndrome2
- Vascular Malformations2
- Klippel Trenaunay Syndrome2